Sino Biopharmaceutical Announces Landmark Phase III Results for TQB3454 IDH1 Inhibitor in Biliary Tract Cancer

Hong Kong, 12 March 2026 — Sino Biopharmaceutical Limited (HKEX: 1177) has made a significant announcement with potentially major implications for shareholders and the broader pharmaceutical market. The company has reported positive results from the Phase III clinical study of TQB3454, an IDH1 inhibitor developed by its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ), targeting advanced biliary tract cancer (BTC) with IDH1 mutations.

Key Highlights of the Announcement

• Phase III Clinical Success: The study completed a pre-specified interim analysis, with both primary endpoints — progression-free survival (PFS) and overall survival (OS) — successfully met. This is a critical milestone indicating the drug’s effectiveness in slowing disease progression and improving patient survival.
• Regulatory Progress: Sino Biopharmaceutical has obtained written approval from China’s Center for Drug Evaluation (CDE), part of the National Medical Products Administration (NMPA), to proceed with the marketing application for this indication. The submission will occur shortly, fast-tracking potential market entry.
• Global and Domestic Firsts: This is only the second successful Phase III trial globally of an IDH1 inhibitor in BTC, and the first such success in China, positioning Sino Biopharmaceutical as a leader in precision oncology for BTC.

Details on the TQB3454 Clinical Trial

• Study Design: The TQB3454-III-01 study (NCT05987358) was a randomized, double-blind, placebo-controlled, multicenter Phase III trial. It enrolled patients with advanced BTC harboring IDH1 mutations who had previously failed standard gemcitabine and fluorouracil-based therapies.
• Clinical Outcomes: Interim analysis demonstrated that TQB3454 significantly reduced the risk of disease progression or death compared with placebo, delivering substantial improvements in both PFS and OS. The safety profile was consistent with previous data, and no new safety signals were identified.
• Next Steps: Detailed trial data will be presented at a major international academic conference later this year, boosting the company’s visibility and credibility in the oncology sector.

Market and Disease Context

• Biliary Tract Cancer (BTC): BTC encompasses cholangiocarcinoma and gallbladder cancer, making up about 3% of all digestive system tumors. In 2021, there were over 200,000 new cases globally, with incidence rates rising. BTC is highly malignant, with a 5-year survival rate below 5%. Most patients are diagnosed at advanced stages and only 10-20% are eligible for curative surgery, with a high recurrence rate post-surgery.
• Unmet Clinical Need: Currently, there are no approved IDH1 inhibitors for BTC in China, leaving a substantial gap in precision therapy options. TQB3454 is the first domestic IDH1 inhibitor poised to fill this gap.
• Breakthrough Designation: TQB3454 was granted Breakthrough Therapeutic Designation by the CDE in April 2023, highlighting its potential for rapid development and review.

Implications for Shareholders and Potential Price Sensitivity

• Market Leadership: As the first domestic IDH1 inhibitor with positive Phase III results, Sino Biopharmaceutical is well-positioned to capture a significant share of the BTC treatment market in China. This could drive substantial revenue growth upon approval and launch.
• Accelerated Approval: With breakthrough status and successful clinical endpoints, regulatory approval and commercialization may be expedited, potentially impacting earnings forecasts and valuation.
• Competitive Advantage: The company’s success in BTC, a disease with high unmet need and poor prognosis, may enhance its reputation and attract further investment or partnership opportunities.

Board and Leadership

• Board Composition: The board is chaired by Ms. Tse, Theresa Y Y, alongside five other executive directors and five independent non-executive directors, ensuring robust governance and oversight.

Conclusion

This announcement represents a major milestone for Sino Biopharmaceutical Limited, with the potential to significantly impact share value. The combination of successful Phase III results, imminent regulatory submission, and first-mover advantage in China’s BTC market makes this news highly price-sensitive. Investors should monitor upcoming conference presentations and regulatory developments closely.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. The information herein is based on publicly available disclosures as of 12 March 2026 and is subject to change.

View SINO BIOPHARM Historical chart here